SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,627.18 |
| Enterprise Value ($M) | 1,947.64 |
| Book Value ($M) | 59.08 |
| Book Value / Share | 0.67 |
| Price / Book | 27.54 |
| NCAV ($M) | -118.35 |
| NCAV / Share | -1.33 |
| Price / NCAV | -13.75 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.70 |
| Return on Assets (ROA) | -0.48 |
| Return on Equity (ROE) | -4.34 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.04 |
| Current Ratio | 2.08 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 416.70 |
| Assets | 594.12 |
| Liabilities | 535.05 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 233.18 |
| Operating Income | -256.18 |
| Net Income | -321.55 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -237.47 |
| Cash from Investing | 99.33 |
| Cash from Financing | 139.42 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 7.50 | -16.57 | |
| 13G/A | Woodline Partners LP | 2.40 | -51.29 | |
| 13G/A | Armistice Capital, Llc | 9.62 | -3.79 | |
| 13G/A | Rock Springs Capital Management LP | 5.72 | 12.73 | |
| 13G/A | Macquarie Group Ltd | 4.90 | -10.25 | |
| 13G/A | Vanguard Group Inc | 7.75 | -2.32 | |
| 13G/A | Deep Track Capital, LP | 0.70 | -92.93 | |
| 13G/A | Morgan Stanley | 1.70 | -68.22 | |
| 13G/A | State Street Corp | 3.60 | -48.87 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 527,711 | 1,881,503 | 28.05 | |
| 187,546 | 956,618 | 19.61 | |
| 235,818 | 1,242,686 | 18.98 | |
| 279,056 | 1,197,943 | 23.29 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| TNGX – Tango Therapeutics, Inc. | TRDA – Entrada Therapeutics, Inc. |
| TRVI – Trevi Therapeutics, Inc. | URGN – UroGen Pharma Ltd. |
| VCEL – Vericel Corporation |
Financial data and stock pages provided by
Fintel.io